Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
RGEN · against 165 other Healthcare companies of similar size
Ranked #128 of 166 · scores higher than 21% of peers
Bars: peers in each 10-point band of the valuation score14 peers with a valuation score of 30–39, including RGEN · Click a bar to see the companies
Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.
| Metric | RGEN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 165 reported | 0.4% | 2.5% | 27% | 30% | |
| EBITDA yieldHigher is better · 165 reported | 1.4% | 4.7% | 24% | 50% | |
| Free cash flow yieldHigher is better · 100 reported | 1.1% | 2.2% | 40% | 20% | |
| Book yieldHigher is better · 164 reported | 21.0% | 18.7% | 55% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 2 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 3 | 10.4B USD | 96 | 64 | |
| 4 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 5 | 11.6B USD | 94 | 58 | |
| 125 | 9.1B USD | 38 | 74 | |
| 128 | 14.87T KRW (≈$10.7B) | 37 | 76 | |
| 128 | 5.2B USD | 37 | 74 | |
| 128 | 8.6B USD | 37 | 30 | |
| 128 | 10.1B USD | 37 | 61 | |
| 132 | 16.5B USD | 36 | 37 | |
| 133 | 6.1B USD | 33 | ||
| 133 | 5.6B USD | 33 | 53 | |
| 133 | 8.8B USD | 33 | 50 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score